AB-Biotics, S.A. Stock price

Equities

ABB

ES0109659013

Biotechnology & Medical Research

End-of-day quote BME 5-day change 1st Jan Change
- EUR -.--% Intraday chart for AB-Biotics, S.A. -.--% -.--%
Sales 2017 7.72M 8.33M Sales 2018 12.59M 13.59M Capitalization 38.75M 41.82M
Net income 2017 - 0 Net income 2018 1M 1.08M EV / Sales 2017 2.22 x
Net cash position 2017 1.86M 2M Net cash position 2018 2.44M 2.63M EV / Sales 2018 2.88 x
P/E ratio 2017
-21.2 x
P/E ratio 2018
31.7 x
Employees -
Yield 2017 *
-
Yield 2018
-
Free-Float 31.56%
More Fundamentals * Assessed data
Dynamic Chart
AB-Biotics, S.A. acquired Alifarm S.A. for EUR 3.5 million. CI
Kaneka Europe Holding Company N.V. completed the acquisition of 18.21% stake in AB-Biotics, S.A. CI
Kaneka Europe Holding Company N.V. made an offer to acquire remaining 33.67% stake in AB-Biotics, S.A. for €21.2 million. CI
Kaneka Corporation has completed the voluntary offer to acquire an additional 26.57% stake in AB-Biotics, S.A. for €16.7 million. CI
Kaneka Corporation made a voluntary public offer to acquire the remaining 60.24% stake in AB-Biotics, S.A. for €37.9 million. CI
Ab-Biotics Sa Reports Earnings Results for the Full Year Ended December 31, 2018 CI
Kaneka Corporation Concludes License Agreement with AB-Biotics for Production and Sales of its Probiotics Products CI
Kaneka Corporation completed the acquisition of 26.87% stake in AB-Biotics, S.A. from Corporacion Ivamosa, Gestion Y Administracion Mobiliaria, S.A., Capital MAB, FCR fund of Institut Català de Finances Capital, SGEIC, S.A. and Buanaventura Guamis. CI
Kaneka Americas Holding Inc. enters into Licensing Agreement with AB-Biotics, S.A CI
Kaneka Corporation signed an agreement to acquire 26.87% stake in AB-Biotics, S.A. from Corporacion Ivamosa, Gestion Y Administracion Mobiliaria, S.A., Capital MAB, FCR fund of Institut Català de Finances Capital, SGEIC, S.A. and Buanaventura Guamis. CI
Corporacion Ivamosa and Gestion Y Administracion Mobiliaria, S.A. acquired 10% stake in AB-Biotics, S.A.. CI
Frutarom Industries Ltd. acquired AB-Fortis from AB-Biotics, S.A.. CI
AB-Biotics SA announced a financing transaction CI
AB-Biotics Agrees Distribution Deal with Abbott for I3.1 Probiotic in Spain CI
DuPont Nutrition & Health and AB-Biotics Announce Agreement on Probiotic for Cardiovascular Health CI
More news
Members of the board TitleAgeSince
Founder - 04-04-22
Founder - 04-04-22
Director/Board Member - 18-07-01
More insiders
AB-Biotics SA, also known as AB Biotics, is a Spain-based company engaged in the biotechnology industry business sector. It is dedicated to the research and development (R&D) of functional ingredients, drugs and tools for genetic analysis, as well as the nutraceutical and pharmaceutical industries. The Company's pipeline includes a range of supplements designed to improve health, from products that can lower the risk of cardiovascular disease to those that can help in the management of diabetes. It covers the development spectrum from marketed product, to proof-of-concept, and includes products that have been licensed to global food and pharmaceutical companies. The Company also provides outsourced R&D solutions to pharmaceutical companies, as well as functional food industry related companies. The Company offers different products, such as AB-Life, LipiGO, AB-Dentalac and AB-Colic, among others.
More about the company
  1. Stock
  2. Equities
  3. Stock AB-Biotics, S.A. - BME